// App-Quantinova.ai

TPS8060 : Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).

Researchers

Presenter

  • Thomas G. Martin

Principal Investigators

  • Meletios A. Dimopoulos

  • Kwee Yong

  • Joseph Mikhael

  • Marie-Laure Risse

  • Gaelle Asset

  • Philippe Moreau

Medical Centers

  • University of California, San Francisco, San Francisco, CA

  • National and Kapodistrian University of Athens, Athens, Greece

  • Kings College London, London, United Kingdom

  • Mayo Clinic, Phoenix, AZ

  • Sanofi, Alfortville, France

  • Sanofi, Chilly-Mazarin, France

  • University Hospital Nantes, Nantes, France

Locations

  • United States

  • France

  • United Kingdom

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • Isatuximab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Multinational

  • Prospective

Phase

  • III

Study Id's

  • NCT03275285

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved